The challenge of viral reservoirs in HIV-1 infection
JN Blankson, D Persaud… - Annual review of …, 2002 - annualreviews.org
▪ Abstract A viral reservoir is a cell type or anatomical site in association with which a
replication-competent form of the virus accumulates and persists with more stable kinetic …
replication-competent form of the virus accumulates and persists with more stable kinetic …
Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy
T Pierson, J McArthur… - Annual review of …, 2000 - annualreviews.org
The success of combination antiretroviral therapy for HIV-1 infection has generated interest
in mechanisms by which the virus can persist in the body despite the presence of drugs that …
in mechanisms by which the virus can persist in the body despite the presence of drugs that …
HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression
RT Davey Jr, N Bhat, C Yoder… - Proceedings of the …, 1999 - National Acad Sciences
Identifying the immunologic and virologic consequences of discontinuing antiretroviral
therapy in HIV-infected patients is of major importance in developing long-term treatment …
therapy in HIV-infected patients is of major importance in developing long-term treatment …
Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population
Adherence to protease inhibitors, HIV-1 viral load, and deve... : AIDS Adherence to protease
inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population …
inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population …
[HTML][HTML] Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy
GD Sanders, AM Bayoumi, V Sundaram… - … England Journal of …, 2005 - Mass Medical Soc
Background The costs, benefits, and cost-effectiveness of screening for human
immunodeficiency virus (HIV) in health care settings during the era of highly active …
immunodeficiency virus (HIV) in health care settings during the era of highly active …
[HTML][HTML] A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy
Highly active antiretroviral therapy (HAART) can suppress HIV replication to undetectable
levels in plasma, but it is unlikely to eradicate cellular reservoirs of virus. Immunotherapies …
levels in plasma, but it is unlikely to eradicate cellular reservoirs of virus. Immunotherapies …
Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel
PG Yeni, SM Hammer, CCJ Carpenter, DA Cooper… - Jama, 2002 - jamanetwork.com
ObjectiveNew information warrants updated recommendations for the 4 central issues in
antiretroviral therapy: when to start, what drugs to start with, when to change, and what to …
antiretroviral therapy: when to start, what drugs to start with, when to change, and what to …
Prevalence and predictive value of intermittent viremia with combination HIV therapy
ContextIn HIV-infected patients having virologic suppression (plasma HIV RNA< 50
copies/mL) with antiretroviral therapy, intermittent episodes of low-level viremia have been …
copies/mL) with antiretroviral therapy, intermittent episodes of low-level viremia have been …
Genotypic resistance testing of HIV-1 DNA in peripheral blood mononuclear cells
C Chu, D Armenia, C Walworth… - Clinical Microbiology …, 2022 - Am Soc Microbiol
SUMMARY HIV-1 DNA exists in nonintegrated linear and circular episomal forms and as
integrated proviruses. In patients with plasma viremia, most peripheral blood mononuclear …
integrated proviruses. In patients with plasma viremia, most peripheral blood mononuclear …
Genotypic testing for human immunodeficiency virus type 1 drug resistance
RW Shafer - Clinical microbiology reviews, 2002 - Am Soc Microbiol
There are 16 approved human immunodeficiency virus type 1 (HIV-1) drugs belonging to
three mechanistic classes: protease inhibitors, nucleoside and nucleotide reverse …
three mechanistic classes: protease inhibitors, nucleoside and nucleotide reverse …